September 13, 2017 08:00 AM Eastern Daylight Time
EMERYVILLE, Calif.–(BUSINESS WIRE)– Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on developing novel T-cell immunotherapies for the treatment of solid tumors and improving the safety profile of T-cell therapies, today announced that Company management will be participating at the following upcoming industry conferences:
September 26, 2017 at 2:15 pm – 2:45 pm, Boston, MA
Presentation title: The Link Between Process Development and GMP Production
September 27, 2017 at 11:15 am -12:00 pm, Boston, MA
Panel title: Strategize First-In-Human CAR-T and TCR-T Study Designs
Dr. Shon Green, Research Scientist at Eureka Therapeutics, will be presenting at the Cell and Gene Therapy Bioprocessing & Commercialization, which is being held from September 25-27, 2017, as part of Biotech Week Boston. The presentation is titled: The Link Between Process Development and GMP Production. The presentation will address the challenges of developing a GMP cell therapy manufacturing process that is safe and robust despite current limitations in the field and vague regulatory guidelines.
For more information about the conference, including the full agenda, visit https://lifesciences.knect365.com/celltherapy-bioprocessing/.
Dr. Vivien Chan, Vice President of Portfolio Management at Eureka Therapeutics, will be participating on a panel at the FierceBiotech Drug Development Forum, which is being held from September 25-27, 2017. The panel is titled: Strategize First-In-Human CAR-T and TCR-T Study Designs. The participants will discuss: Engineering T cells to provide the same discrimination between friend and foe as endogenous T cells; identifying the indications most fitting for CARs and/or TCRs; and mitigating the costs of genetically modifying T cells.
For more information about the conference, including the full agenda, visit http://www.fiercedrugdevforum.com/.
About Eureka Therapeutics, Inc.
Eureka Therapeutics Inc. is a clinical stage privately held biotechnology company, headquartered in the San Francisco Bay area, focused on developing first-in-class T cell immunotherapies for hematological malignancies and solid tumors and improving the safety profile of T-cell therapies. Its core technology platforms center around the discovery and engineering of fully human antibodies against intracellular targets via the MHCI complex. The company is developing a pipeline of novel cancer therapeutics targeting intracellular oncogenes.
For more information, please visit: www.eurekainc.com.
Eureka Therapeutics, Inc.